2020年7月29日,BNT111的Ⅰ期临床试验结果以《An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma》为题发布在《Nature》上,结果表明,BNT111疫苗接种对患有的黑色素瘤患者是一种有效的免疫疗法,并表明非突变共享肿瘤抗原作为癌症疫苗接种靶点的普遍效用,针对四种黑色素瘤相关抗原的RNA疫苗在黑色素...
BNT111 is an intravenous therapeutic cancer vaccine candidate encoding for a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. More than 90% of melanomas in patients express at least one of...